received saline or escalating doses of Lipopolysaccharide (LPS; 300 ng, 600 ng, 1.2 ug intravenously) over 3 days. The duration of FBMs was assessed using LabChart. PGE 2 expression in brainstem respiratory centres and cerebrospinal fluid (CSF) was assessed by immunohistochemistry and ELISA. Inflammation and cell death in the brainstem were assessed by qRT-PCR. OneWay/Two-Way ANOVA was used for statistical analysis.
The Royal Hospital for Women, Sydney, Australia Email: prithvikaa25@gmail.com Background: Fractional inspired oxygen (FiO 2 ) between 0.21-0.65, adjusted to target preductal SpO 2 levels is recommended for preterm resuscitation. Actual FiO 2 and SpO 2 achieved are unknown.
Aim: To prospectively audit use of oxygen at delivery for infants <32 weeks' gestation.
Methods: An observational study was conducted at 4 hospitals in the USA, Malaysia and Australia between 2017-2018. FiO 2 , SpO 2 and heart rates were recorded for 10 minutes by an uninvolved observer.
Results: Of the 101 infants (USA: 45, Malaysia: 31, Australia: 25), (mean gestation 27.6 AE 2.5 wk, birthweight 1030AE375 g), half (50) were delivered by cesarean section. Mean initial FiO 2 was 0.37 and did not differ: USA, 0.39; Malaysia, 0.33; Australia, 0.38 (range 0.21-1.0). SpO 2 was detected in 98 babies by 5 minutes (mean 79%) but only 61% reached SpO 2 between 80-85%. Mean 5-minute SpO2 was 74%, 87% and 81% (range 23-100) in the centers, respectively. No infant died in the delivery room. Thirteen infants died later (median 9, IQR 3-18 days) from respiratory failure (n = 8) and sepsis (n = 4). Deceased infants versus survivors had no difference in initial Background: Most late preterm and term infants with respiratory distress are cared for in non-tertiary special care nurseries (SCNs). The HUNTER trial enrolled over 750 infants from 9 SCNs. This survey aimed to explore challenges faced, and lessons learned, when conducting the HUNTER trial, the largest randomised trial of respiratory support for newborn infants undertaken in an Australian non-tertiary setting.
Methods: At completion a survey of research staff was conducted. The electronic survey consisted of 18 questions and was distributed to the 13 research nurses and 7 site investigators. Information sought included: demographics, experience with initiating the trial, barriers to recruitment, and overall experience of the research role.
Results: 15 staff responded (9 research nurses 6 site investigators). 73% had no prior experience working in a research role on a randomised controlled trial. Respondents were experienced clinicians: 26% had 5-10years' experience and 60% had >10years experience working in a non-tertiary SCN. The top three barriers to recruitment were; language barrier, parent(s) unavailable to seek consent, and a reluctance of medical staff to approach families. 93% reported the trial was very well or well accepted into the day to day care. All respondents reported being satisfied or very satisfied in their research role with 80% stating they would consider a similar role in a future trial in the non-tertiary setting.
Conclusions: Conducting large scale trials in the non-tertiary setting is achievable. With adequate funding and leadership we can establish a culture of research to improve treatments for infants in the non-tertiary setting. Methods: In 2016, the FMC Neonatal Unit implemented a protocol transitioning from intravenous to oral caffeine when 1-2 mL/h of milk is tolerated. A retrospective audit of caffeine use was conducted in the 12 months pre-and post-implementation of the protocol. Per annum total costs of intravenous and oral caffeine for each year were normalised by dividing cost by total inpatient bed days for all babies born at <34 weeks gestation until
COST-EFFECTIVENESS OF TRANSITIONING FROM INTRAVENOUS TO ORAL CAFFEINE CITRATE ONCE TOLERATING MINIMAL ENTERAL FEEDS

